Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clover Biopharmaceuticals Ltd. has announced positive preliminary results from their Phase I trial for their bivalent RSV vaccine candidate, SCB-1019, showing promising immunogenicity and safety in older adults. The vaccine, leveraging the company’s Trimer-Tag technology, demonstrated high neutralizing antibody titers and a favorable safety profile, with no serious adverse events reported. These results suggest SCB-1019 may offer a competitive edge in the global vaccine market, with full Phase I data expected by the end of 2024.
For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.